相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bayesian inference on the number of recurrent events: A joint model of recurrence and survival
Willem van den Boom et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2022)
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
Christine H. Chung et al.
CANCERS (2021)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco et al.
LANCET ONCOLOGY (2021)
Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
Rene Bruno et al.
CLINICAL CANCER RESEARCH (2020)
Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma
Daniel J. Glazar et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung Cancer
Mario Nagase et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Dynamic Prediction of Outcome for Patients With Ovarian Cancer: Application of a Joint Model for Longitudinal Cancer Antigen 125 Values
Yuting Cao et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris et al.
CANCER TREATMENT REVIEWS (2018)
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review
Mallika Lala et al.
ORAL ONCOLOGY (2018)
Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer
Solene Desmee et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saada-Bouzid et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients
Laurent Claret et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials
R. Bruno et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma
Peter L. Bonate et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling
M. L. Maitland et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Nonlinear nonparametric mixed-effects models for unsupervised classification
Laura Azzimonti et al.
COMPUTATIONAL STATISTICS (2013)
Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
E. K. Hansson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
E. K. Hansson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial
Andrew Stein et al.
BMC CANCER (2012)
A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy
Benjamin Ribba et al.
CLINICAL CANCER RESEARCH (2012)
Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time-to-Event Data
Dimitris Rizopoulos
BIOMETRICS (2011)
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer
N. Frances et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
Wilfred D. Stein et al.
CLINICAL CANCER RESEARCH (2011)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer
Laurent Claret et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach
Cecile Proust-Lima et al.
BIOSTATISTICS (2009)
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine plus carboplatin in non-small cell lung cancer patients
Lai-San Tham et al.
CLINICAL CANCER RESEARCH (2008)
分享论文
